www.nytimes.com
3 months agoBiogen Abandons Its Controversial Alzheimer's Drug Aduhelm
Biogen is abandoning its ownership rights to the Alzheimer's drug Aduhelm, after it failed to gain traction in the market.
The decision to abandon Aduhelm comes after the drug faced criticism for its weak evidence of efficacy, high price, and safety risks. [ more ]